Featured Article

Celecoxib Modulates the Capacity for Prostaglandin E\(_2\) and Interleukin-10 Production in Alveolar Macrophages from Active Smokers

Jenny T. Mao,1 Michael D. Roth,1 Kenneth J. Serio,3 Felicita Baratelli,1 Li Zhu,1 E. Carmack Holmes,2 Robert M. Strieter,1 and Steven M. Dubinett1

1Division of Pulmonary and Critical Care Medicine and 3Department of Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, and 1Division of Pulmonary and Critical Care Medicine, VA San Diego Healthcare System and the University of California, San Diego, California

Abstract

Purpose: Preclinical data suggest that the cyclooxygenase (COX)-2prostaglandin (PG) E\(_2\) signaling pathway plays an essential role in conferring the malignant phenotype in non-small cell lung cancer. We hypothesized that treatment with oral celecoxib, a selective COX-2 inhibitor, would favorably alter biomarkers of lung cancer risk. This study evaluated the feasibility of COX-2 inhibition as a form of chemoprevention for lung cancer.

Experimental Design: Heavy active smokers were enrolled into a pilot study and treated with celecoxib. Bronchoscopy with bronchoalveolar lavage was performed both before and after 1 month of celecoxib treatment to recover alveolar macrophages (AMs) and lining fluid for study. After harvest, AMs were immediately stimulated in vitro with the calcium ionophore A23187. AMs obtained from smokers before treatment and from nonsmoking control subjects were also cultured overnight with SC58236, a selective COX-2 inhibitor, with or without lipopolysaccharide stimulation.

Results: Treatment with celecoxib significantly reduced calcium ionophore-stimulated PGE\(_2\) production from AMs recovered from smokers. AMs recovered from smokers, but not nonsmokers, were primed to produce high levels of PGE\(_2\) and interleukin (IL-10) when stimulated with lipopolysaccharide, and SC58236 significantly abrogated the production of these factors. Moreover, both plasma and bronchoalveolar lavage fluid obtained from treated subjects significantly reduced the production of PGE\(_2\) that resulted when a lung cancer cell line, A549, was stimulated with IL-1\(\beta\) or A23187.

Conclusions: Our findings suggest that oral celecoxib is capable of inhibiting the overproduction of PGE\(_2\), as well as modulating the production of IL-10 in the lung microenvironment in individuals at risk for lung cancer.

Introduction

Accumulating evidence suggests that NSAIDs\(^4\) that inhibit the synthesis of PGs can reduce the incidence of a variety of cancers. The evidence derives from rodent models of chemical-induced carcinogenesis (1), epidemiological studies, and clinical trials in patients with familial adenomatous polyposis (2). COXs (COX-1 and COX-2) are enzymes that catalyze the formation of PGs from arachidonic acid (3). Whereas COX-1 is involved in the homeostasis of various physiological functions, COX-2 is up-regulated in response to a variety of stimuli including growth factors, cytokines, and carcinogens and is responsible for many inflammatory processes. The simultaneous inhibition of COX-1 (constitutively expressed) and COX-2 (inducible isoform), however, interferes with the maintenance functions of COX-1 and thereby increases the risk of serious side effects, such as peptic ulcer disease. This problem may be avoided by selective inhibition of the COX-2 enzyme (4, 5).

Many effects of NSAIDs on cancer have been ascribed to the effects of these drugs on COX-2. COX-2 has been implicated in the development of colon cancer and may play a role in promoting invasion, metastasis, angiogenesis, and resistance to apoptosis, as well as suppression of antitumor immunity in several tumor types (6–11). Our laboratory first reported the presence of COX-2 protein in squamous cell carcinomas and adenocarcinomas of the lung (11). Others also reported similar findings (12–14). In addition, COX-2 protein is overexpressed in preneoplastic alveolar epithelium, suggesting its role in tumorigenesis (15).

Animal models and human trials for colon cancer suggest that systemic inhibition of COX-2 can act as an effective chemopreventive therapy. In a very similar manner, treatment with COX-2-specific inhibitors protects mice from lung tumorigen-
Clinical studies have demonstrated a relationship between the overexpression of COX-2 and lung cancer, overexpression of COX-2 and/or PGE2 is associated with a variety of well-established lung cancer risk factors, including antitumor immunity via an imbalance between the production of IL-10 and IL-12 by both tumors and immune regulatory cells, such as peripheral blood lymphocytes, macrophages, and dendritic cells (11, 16–19). Overproduction of PGE2 in the lung microenvironment also produces immunosuppressive effects on T cells, natural killer cells, and antigen-presenting cells, resulting in enhanced tumor growth (20, 21).

As part of a pilot study to evaluate the feasibility of celecoxib as a chemopreventive agent for lung cancer, 20 heavy current smokers were recruited and treated with a 6-month course of oral celecoxib. To determine the effects of celecoxib on altering surrogate end point biomarkers of carcinogenesis in the lung, serial bronchoscopies with BAL were performed. Treatment with oral celecoxib inhibited the production of PGE2 when AMs were stimulated ex vivo with A23187. In addition, AMs from pretreatment samples were cultured overnight with SC58236, a COX-2-selective inhibitor, with or without LPS stimulation. SC58236 significantly abrogated the LPS-induced overproduction of PGE2. Stimulation of AMs with LPS also significantly induced IL-10 production, and SC58236 decreased this effect. Moreover, plasma and BAL fluid obtained from treated subjects abrogated the capacity for IL-1β and A23187 to stimulate PGE2 production by human NSCLC cells in vitro, respectively. These results support the hypothesis that oral administration of celecoxib is capable of modulating the intrapulmonary production of PGE2 and IL-10 and may favorably impact on these procarcinogenic forces within the lung microenvironment.

Materials and Methods

**Celecoxib Clinical Study Design.** Active heavy smokers 45 years of age or older, with a smoking history of at least 20 pack-years, were recruited and treated with oral celecoxib (Celebrex; Pfizer, New York, NY) at a dose of 400 mg twice daily for 6 months. Written informed consent was obtained in accordance with the UCLA Institutional Review Board. Patients were screened with chest X-ray and fluorescence (LIFE) bronchoscopy (Xillix, Vancouver, Canada) to rule out the presence of lung cancer. Only subjects without evidence of lung cancer at baseline who met all entry criteria (Table 1) were enrolled. All patients underwent repeat white light bronchoscopy with BAL at 4 weeks after starting treatment and are scheduled to undergo repeat LIFE bronchoscopy at 6 months. Serial bronchial mucosal biopsies, BAL fluid, and blood specimens are being collected for biomarker analyses to determine treatment responses. Bronchoscopy with BAL was also performed in a group of healthy nonsmokers to provide control AMs for comparison studies.

**Blood Samples.** Plasma samples collected in vacutainer tubes containing EDTA were obtained from subjects at baseline, 1 month, and 6 months of treatment. Samples were stored at −80°C until analysis.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Study enrollment criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion</strong></td>
<td><strong>Exclusion</strong></td>
</tr>
<tr>
<td>Age ≥ 45 (yrs)</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Smoking history ≥ 20 pack-years</td>
<td>Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes</td>
</tr>
<tr>
<td>Concurrent use of NSAI ds</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Hypersensitivity to celecoxib or NSAIDs</td>
<td>Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes</td>
</tr>
<tr>
<td>Documented allergic-type reaction to sulfonamides</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Liver dysfunction</td>
<td>Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes</td>
</tr>
<tr>
<td>Hypertension or cardiac conditions aggravated by fluid retention and edema</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Previous history of gastrointestinal ulceration, bleeding, or perforation</td>
<td>Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>End stage respiratory disease (e.g., FEV1 &lt; 0.8 liters, resting or exertional hypoxemia)</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Other malignancy</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Patients with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow-up schedule</td>
</tr>
</tbody>
</table>

**BAL and in Vitro Stimulation of AMs.** Subjects were prepped with a combination of topical anesthesia (20% benzocaine spray to pharynx plus 2% topical lidocaine as needed) and conscious sedation using midazolam and meperidine according to institutional guidelines. A fiberoptic bronchoscope (Olympus BF20D, Olympus America Inc., Melville, NY) was advanced into the airway and wedged into a subsegment of the right middle lobe. Forty-60 ml aliquots of room temperature saline were serially lavaged and recovered by manual suctioning. Recovered fluid was passed through a 100-µm sterile nylon filter (Becton Dickinson, San Jose, CA) to remove mucus and particulates, pooled, and centrifuged at 300 x g for 8 min at 4°C. The BAL fluid was then harvested, aliquoted, and stored at −80°C until analysis.

PGE2 production was stimulated by two methods. For calcium ionophore stimulation, BAL cell pellets were first washed in HBSS (Sigma-Aldrich, St. Louis, MO) and then resuspended in X-Vivo 15 serum-free medium (Biowhittaker, Walkersville, MD) to a concentration of 5 x 10⁶ cells/ml. Cells were incubated with 2 µM A23187 (Calbiochem, San Diego, CA) for 30 min, and the culture supernatants were harvested and stored at −80°C until analysis. BAL cells were also washed once in PBS (Irvine Scientific, Santa Ana, CA) and resuspended in X-Vivo 15 serum-free medium (Biowhittaker) to a concentration of 0.5 x 10⁶ cells/ml. Control cells and cells stimulated with 5 µg/ml LPS (Escherichia coli 026:B6; Sigma-Aldrich) were cultured with or without SC58236, a selective COX-2 inhibitor belonging to the same 1,5-diarylpyrazole class of COX-2 inhibitors as celecoxib (800 ng/ml; Pfizer; Ref. 22) at 37°C. After 24 h of incubation, the conditioned supernatants were harvested and stored at −80°C until analysis. Stock solutions of SC58236 were prepared at a concentration of 1 mg/ml in DMSO and stored at −80°C.

**Effects of Subjects’ Plasma and BAL Fluid on Production of PGE2 by a NSCLC Cell Line.** Most human NSCLC cells produce PGE2 when stimulated (11). As a model for the...
on the production of PGE 2 by cultured AMs and A549 cells

100 units/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM
ml of RPMI 1640 supplemented with 10% fetal bovine serum,
plated in 800

H9262

measured by EIA using a PGE2 EIA kit (Caymen Chemical,
conditioned AMs, and tumor cell culture supernatant were
previously (11). The human IL-12 ELISA kit was obtained from
R&D System (Minneapolis, MN), and the assay was performed
according to the manufacturer's instructions.

Measurement of IL-10 and IL-12 Production in AMs.
Measurement of IL-10 and IL-12 in vitro. Cells were maintained as monolayers in an atmosphere of 5%
CO2 in air at 37°C in 25-cm² tissue culture flasks containing 5.0
ml of RPMI 1640 supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM glutamine (JRH Biosciences, Lenexa, KS). For coculture with
BAL fluid, 8 × 10⁵ A549 cells were plated in wells from a
12-well plate in 700 µl of RPMI 1640 and incubated at 37°C for
2 h. Matched BAL fluids (300 µl) obtained from subjects before and after 1 month of treatment or RPMI 1640 were then added (final concentration, 30%), and cells were incubated at 37°C for
an additional hour, followed by stimulation with A23187 (2 µM)
for 30 min. For cocultures with plasma, 3 × 10⁵ cells were
plated in 800 µl of RPMI 1640 in a 12-well plate and incubated at 37°C for 2 h. Two hundred µl of plasma obtained before
treatment and after 1 month of treatment were added (final
concentration, 20%), and cells were incubated at 37°C for an
additional hour. Cells were then stimulated with IL-1β (200
units/ml) for 24 h. All culture supernatants were harvested and
stored at −80°C until analysis.

Measurement of PGE 2 . PGE 2 concentrations in BAL,
conditioned AMs, and tumor cell culture supernatant were
measured by EIA using a PGE2 EIA kit (Caymen Chemical,
Ann Arbor, MI). Absorbance was determined at 405 nm by
Molecular Devices Microplate Reader (Sunnyvale, CA).

Measurement of IL-10 and IL-12 Production in AMs.
IL-10 and IL-12 levels were measured by ELISA. Rat antihuman
IL-10 capture antibody and rat biotinylated antihuman
IL-10 monoclonal antibody pairs were obtained from PharMin
gen (San Diego, CA). ELISA was performed as described
previously (11). The human IL-12 ELISA kit was obtained from
R&D System (Minneapolis, MN), and the assay was performed
according to the manufacturer’s instructions.

Statistical Analysis. The effects of celecoxib on in-
trapulmonary PGE 2 production were determined by comparing
baseline BAL levels with those obtained at 1 month during
treatment using paired t tests. Similarly, the effects of celecoxib
on the production of PGE 2 by cultured AMs and A549 cells
were determined by paired t tests. Batch analyses were
performed for each subject/comparison group to eliminate interas-
say variability.

Results

Subject Characteristics. The patient cohort consisted of
9 males and 11 females with a mean age of 54 years and a mean
smoking history of 42 pack-years (Table 2). Ten subjects had
evidence of airflow obstruction defined as a forced expiratory
volume in one second < 80% predicted (mean of 66%). Five
subjects had at least one family member with a history of lung
cancer. The celecoxib dose of 400 mg twice daily was well
tolerated with no serious adverse events reported to date. All 20
subjects have completed the 1-month follow-up bronchoscopy,
but longer term follow-up is still ongoing. Four healthy non-
smokers without respiratory symptoms or airflow obstruction
also underwent bronchoscopy (mean age, 30 years of age).

Orally Administered Celecoxib Modulates the Capacity
for AMs to Produce PGE 2 in Active Smokers. BAL fluids
obtained from active smokers before and after 1 month of treat-
ment with celecoxib were first analyzed for relative changes in
the concentrations of PGE 2 as a measure of its effect on COX-2
activity within the lung microenvironment. However, PGE 2
levels in BAL fluid were generally below the level of detection
for EIA (data not shown). We therefore evaluated the effect of
celecoxib therapy on the calcium ionophore-stimulated produc-
tion of PGE 2 by BAL cells. As reported previously, BAL cells
collected from active smokers consisted of >90% AMs (23).
Freshly isolated AMs collected from six subjects before and
after celecoxib treatment were stimulated with A23187 for 30
min. On the average, A23187 caused more than a 3-fold in-
crease in PGE 2 production by cells obtained at baseline, before
celcoxib treatment. In contrast, AMs recovered from subjects
after treatment with oral celecoxib were refractory to A23187
with the production of PGE 2 inhibited by 69%, as compared
with the baseline response (Fig. 1; mean ± SE; P < 0.01;
n = 6).

Plasma and BAL Fluid Obtained from Treated Sub-
jects Abrogated PGE 2 Production by Stimulated NSCLC
Cells in Vitro. COX-2 expression is up-regulated when
NSCLC cells are stimulated with inflammatory cytokines
such as IL-1β. The resultant overproduction of PGE 2 by
tumor cells has been implicated as a driving force for carci-
nogenesis (11, 16). We evaluated plasma and BAL fluid to
determine whether oral celecoxib produced an environment
capable of reducing PGE 2 production in tumor cells. To
induce production of PGE 2, A549 cells were either stimulated

Table 2  Baseline subject characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>54</td>
<td>47–78</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>9/11</td>
<td></td>
</tr>
<tr>
<td>Smoking history (pack-yrs)</td>
<td>42</td>
<td>20–159</td>
</tr>
<tr>
<td>Ethnicity, A/B/C/H</td>
<td>1/2/15/2</td>
<td></td>
</tr>
<tr>
<td>COPD (n)</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Family history of lung cancer (n)</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

* A/B/C/H, Asian/Black/Caucasian/Hispanic.
* COPD, chronic obstructive pulmonary disease.
for 24 h with IL-1β or stimulated for 30 min with A23187. Stimulation of A549 cells with IL-1β in control media increased PGE₂ production on average by 5-fold. Addition of baseline plasma augmented this to a 10-fold increase. However, the addition of plasma from patients receiving celecoxib almost completely abrogated this induction. Similarly, post-treatment BAL fluid also abrogated the capacity for A23187 to increase PGE₂ production in A549 cells by 85% (Fig. 2, A and B; mean ± SE; P < 0.01; n = 3).

In Vitro Treatment with SC58236 Blocks LPS-Induced Production of PGE₂ by AMs Recovered from Smokers.

Oral administration of celecoxib blocked the capacity for stimulated AMs to produce PGE₂. To model this effect in vitro, BAL cells recovered from smokers before treatment were cultured for 24 h in media containing the COX-2 inhibitor SC58236 (800 ng/ml). Concentrations of PGE₂ in the culture supernatant were reduced by an average of 82% compared with untreated cells. Stimulation with LPS significantly increased the PGE₂ production by an average of 17.5-fold, and coculture with SC58236 abrogated the LPS-induced PGE₂ production by an average of 75% (P < 0.05). Interestingly, AMs from nonsmokers were less responsive to LPS and produced lower levels of PGE₂ when stimulated. However, addition of SC58236 still blocked the response to LPS in nonsmoker AMs. These data suggest that AMs from active smokers are primed to produce higher levels of PGE₂ when exposed to inflammatory stimuli (Fig. 3).

Inhibition of COX-2 Blocks the Release of IL-10 by LPS-Stimulated AMs from Smokers, but not from Nonsmokers.

Changes in IL-10 production were also analyzed in the same sets of conditioned AM cell culture supernatants as described above. LPS significantly induced the production of IL-10 by an average of 12.8-fold, and treatment with SC58236 significantly reduced LPS-induced IL-10 production by an average of 24% (n = 10).

Discussion

This pilot study focused on the feasibility of using an oral COX-2 inhibitor, celecoxib, as a chemopreventive agent to...
To further understand the potential significance of celecoxib treatment on lung carcinogenesis, we evaluated the functional effects of bronchoalveolar lining fluid and plasma obtained from treated subjects on the synthesis of PGE2 by the human NSCLC cell line A549. Plasma obtained from baseline significantly increased the stimulatory effect of IL-1β on PGE2 production, and plasma from treated subjects completely abrogated the IL-1β-induced up-regulation of PGE2 by A549 cells. Presumably, tobacco smoke may have generated proinflammatory mediators in the plasma that synergistically augmented the effects of IL-1β in the culture medium. For example, Ryder et al. (24) reported that peripheral blood mononuclear cells from tobacco smokers produced more IL-1β and transforming growth factor β than those of nonsmokers. Alternatively, certain plasma factors may be required for IL-1β to exert its maximal stimulatory effect on COX-2 induction. Similarly, posttreatment BAL fluid also abrogated the capacity for A23187 to induce PGE2 synthesis. These findings, although indirect, further support the notion that oral celecoxib either reached a high enough concentration in the lung microenvironment to directly impair PGE2 production by tumor cells or altered other host-derived endogenous proteins or cytokines capable of indirectly inhibiting PGE2 production. Our findings also corroborate with the recent report by Altorki et al. (25) that coadministration of oral celecoxib (400 mg, twice daily) was sufficient to normalize the marked increase in intratumoral PGE2 levels found in NSCLC patients after treatment with paclitaxel and carboplatin.

PGE2 is an important COX-2 dependent regulator of cell-mediated immunity and a potent inducer of Th2 immune responses (16). It up-regulates the synthesis of IL-10 in a variety of immune-regulatory cells and suppresses Th1 responses (26–31). One of the mechanisms by which PGE2 may facilitate tumorigenesis is via the suppression of antitumor immunity. Tumor-derived PGE2 has been shown to inhibit host antitumor immunity by creating an imbalance between the production of IL-10 and IL-12 in lymphocytes and macrophages. Both IL-10 and IL-12 are critical regulatory elements of cell-mediated antitumor immunity. Whereas IL-12 induces type 1 cytokine production and effective antitumor cell-mediated responses (18, 26), IL-10 overproduction at the tumor site has been implicated in tumor-mediated immune suppression. IL-10 has the capacity to inhibit antitumor responses through several pathways such as limiting type 1 cytokine production (28–30), antigen presentation (32, 33), and antigen-specific T-cell proliferation (34). In a murine Lewis lung carcinoma model, COX-2 inhibition decreased IL-10 and restored IL-12 production by antigen-presenting cells. Restoration of the balance between IL-10 and IL-12 in vivo promoted antitumor immunity, resulting in concomitant reduction of tumorigenesis (26).

AMs play a key role in modulating local immune functions (35). They are the first major cell type to encounter inhaled toxins and are responsible for the clearance of these particles. As part of the natural defense against unwanted alveolar inflammation and airway reactivity, human AMs can secrete high levels of PGE2 that can prevent the cytokine-induced activation of T cells and natural killer cells (20, 21). In this study, we found that 800 ng/ml SC58236 significantly reduced both constitutive and LPS-induced PGE2 production by AMs from active smokers. In addition, SC58236 significantly reduced both constitutive and LPS-induced IL-10 production by AMs from active smokers, without altering the production of IL-12. To our knowledge, this is the first report demonstrating that COX-2 inhibition down-regulates IL-10 production by LPS-stimulated human AMs from smokers. It is conceivable that cigarette smoking may have created an immunosuppressive environment in the respiratory tract of active smokers, in part, by altering this cytokine network through the COX-2/PGE2 signaling pathway. It is notable that
this down-regulation of IL-10 occurred in 8 of the 10 subjects, suggesting that this response may be heterogeneous. The precise mechanisms that may account for this heterogeneity are unclear.

It is also of interest that the response to celecoxib in BAL cells recovered from active smokers differed from that observed with cells obtained from healthy nonsmokers. Unstimulated AMs from smokers produced significantly more PGE$_2$ than those from nonsmokers, suggesting that tobacco smoking up-regulates the expression of COX-2. This is further supported by the fact that treatment with SC58236 reduced AM PGE$_2$ production to a similar level in both smokers and nonsmokers. These findings are consistent with previous studies suggesting that benzo(a)pyrene, a polycyclic aromatic hydrocarbon in tobacco smoke, has the capacity to induce COX-2 gene transcription (36, 37). Thus, tobacco-derived products may act directly to up-regulate COX-2. Alternatively, tobacco products may induce cytokine and inflammatory cascades leading to the induction of AM COX-2 expression. In addition, tobacco smoking appears to have “primed” the AMs to the stimulatory effect of LPS because both the stimulatory effect of LPS and the inhibitory effects of SC58236 on AM PGE$_2$ production from nonsmokers are much less dramatic than those in smokers. Furthermore, AMs from nonsmokers produced less IL-10 in response to LPS than those from smokers, and SC58236 had no effect on LPS-stimulated IL-10 production in nonsmokers.

The fact that SC58236 does not completely block the LPS-induced IL-10 production in AMs of smokers suggests that other COX-2-independent mechanisms are involved in the up-regulation of IL-10 in response to LPS stimulation. LPS is known to produce immunomodulatory effects in AMs via a variety of mechanisms, including activation of second messenger pathways (38). Our data suggest that the differences in responsiveness to LPS between smokers and nonsmokers may be due to up-regulation of COX-2 enzymes in AMs by tobacco smoke. Celecoxib may therefore be more effective at protecting against active carcinogenic forces in smokers. This notion is further supported by a recent study in an AM cell line demonstrating that 4-(methylnitrosamo)-1-(3-pyridyl)-1-butanoine, the tobacco-specific nitrosamine, augmented LPS-induced IL-10 production in these AMs (39).

However, because COX-2 inducibility may be affected by aging (40), the age differences in our smoking and nonsmoking cohorts may account, in part for these observed disparities among smokers and nonsmokers. Nevertheless, this heightened inflammatory responsiveness to stimuli is likely a main contributor of the clinical diseases and symptoms associated with tobacco smoking.

In summary, results from interim analysis of this pilot study suggest that oral celecoxib is capable of impacting the lung microenvironment by blocking the overproduction of PGE$_2$ in active smokers. In addition, celecoxib may be able to reverse the immunosuppressive effect from tobacco smoking by reversing the imbalance between IL-10 and IL-12 production in AMs, which may in turn restore antitumor immunity in the lungs of smokers. These findings support the potential and continued investigation of celecoxib as a chemopreventive agent for lung cancer.

Acknowledgments

We thank Jessica Bailow, Brad Adams, Angela Tsu, Thy Dana, Grace Ibrahim, and John Dermand for excellent technical assistance and Jaime Masferrer (Pfizer) for helpful discussion and for generously supplying SC58236.

References

16. Huang, M., Sharma, S., Mao, J. T., and Dubinett, S. M. Non-small cell lung cancer-derived soluble mediators and prostaglandin E$_2$ en-


Celecoxib Modulates the Capacity for Prostaglandin E₂ and Interleukin-10 Production in Alveolar Macrophages from Active Smokers

Jenny T. Mao, Michael D. Roth, Kenneth J. Serio, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/9/16/5835

Cited articles
This article cites 34 articles, 22 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/9/16/5835.full#ref-list-1

Citing articles
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/9/16/5835.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/9/16/5835.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.